Correlation Between Maat Pharma and Dow Jones

Can any of the company-specific risk be diversified away by investing in both Maat Pharma and Dow Jones at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Maat Pharma and Dow Jones into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Maat Pharma SA and Dow Jones Industrial, you can compare the effects of market volatilities on Maat Pharma and Dow Jones and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Maat Pharma with a short position of Dow Jones. Check out your portfolio center. Please also check ongoing floating volatility patterns of Maat Pharma and Dow Jones.

Diversification Opportunities for Maat Pharma and Dow Jones

0.45

Correlation Coefficient

Maat Pharma  Dow Jones

Very weak diversification

The 3 months correlation between Maat and Dow is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Maat Pharma SA and Dow Jones Industrial in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dow Jones Industrial and Maat Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Maat Pharma SA are associated (or correlated) with Dow Jones. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dow Jones Industrial has no effect on the direction of Maat Pharma i.e., Maat Pharma and Dow Jones go up and down completely randomly.

Pair Corralation between Maat Pharma and Dow Jones

Assuming the 90 days trading horizon Maat Pharma SA is expected to under-perform the Dow Jones. In addition to that, Maat Pharma is 3.83 times more volatile than Dow Jones Industrial. It trades about -0.11 of its total potential returns per unit of risk. Dow Jones Industrial is currently generating about -0.04 per unit of volatility. If you would invest  4,257,373  in Dow Jones Industrial on December 29, 2024 and sell it today you would lose (98,983) from holding Dow Jones Industrial or give up 2.32% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	93.85%
Values	Daily Returns

Maat Pharma SA  vs.  Dow Jones Industrial

Pair Trading with Maat Pharma and Dow Jones

The main advantage of trading using opposite Maat Pharma and Dow Jones positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Maat Pharma position performs unexpectedly, Dow Jones can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dow Jones will offset losses from the drop in Dow Jones' long position.

The idea behind Maat Pharma SA and Dow Jones Industrial pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.